Introduction
In insulin-dependent diabetics, plasma growth hormone (GH) levels are usually elevated and show more frequent and higher peaks compared with nondiabetics (Hansen and Johansen, 1970; Corral et al., 1974) . Plasma GH levels are also raised more easily in diabetics by stimuli such as exercise (Hansen, 1970 (Hansen, , 1971 , arginine (Passa, Rousselie and Ganville, 1977) and glucagon (Waldhausl et al., 1976) . These quantitative differences in GH responses may partly explain the raised plasma GH levels in diabetics, but, in addition there may be qualitative differences in GH release as occurs in anorexia nervosa (Maeda et al., 1976; Harrower et al., 1977b) and chronic renal failure (Gonzalez-Barcena et al., 1973; Czernikow et al., 1976) where plasma GH levels are also often raised. In these conditions, thyrotrophin-releasing hormone (TRH) may stimulate GH release, an effect which does not occur in normal subjects, but which is similar to that reported in acromegalic patients (Irie and Tsushima, 1972; Luizzi et al., 1974; Gomez-Pan et al., 1975; Harrower et al., 1977a) . If a similar effect occurs in diabetics then this would contribute further to GH release, ensuring that diabetic patients are exposed to high plasma GH levels for considerable periods of time.
To determine whether GH release in diabetics is modified by TRH, the author studied the effect of this hormone on plasma GH levels in a group of insulin-dependent diabetics. The effect of TRH on plasma prolactin (PRL) and thyrotrophin (TSH) levels was also investigated to ensure that an adequate stimulus had been given and also to determine whether PRL and TSH were released normally in response to this stimulus in such patients.
Patients and methods
Fifteen insulin-dependent diabetic patients (9M and 6F) gave informed consent to the study. All were hospital in-patients at the time and clinical details are shown in Table 1 . After an overnight fast an intravenous butterfly needle (Abbott) was inserted into a forearm vein at least 30 min before blood sampling began: the needle was kept patent with heparinized saline. In each patient, after a baseline sample had been taken, 500 ,ug TRH (Roche) was injected and further blood samples taken after 20, 30, 60 and 90 min. Plasma was separated and stored at -20°C for later analysis. All specimens were assayed for GH (Schalch and Parker, 1964) , TSH (Irvine et al., 1973) and PRL (Reuter et al., 1976) by radioimmunoassay and for glucose with a Technicon autoanalyser using a glucose oxidase method. For the purposes of the study a 2-fold or greater rise in plasma GH was considered significant.
Results
Basal plasma GH levels were raised above 5 mu./l in 6 patients (Table 2, nos 1,4,7, 10, 11 and 13) . Following the injection of TRH, plasma GH levels rose significantly in 9 patients (nos 1-5, 8, 9, 12 and 15). The rise in plasma GH from basal to peak levels was significant in the group as a whole (P < 0 01) (Fig. 1 ) and the mean (±s.e. mean) values at each time of sampling are shown in Fig. 2 and Table 2 .
Basal plasma PRL levels were normal in all 15 (Fig. 3) . Basal TSH levels were also normal in all 15 patients and rose normally in response to TRH (Fig. 4) (1930) showed that hypophysectomy ameliorated diabetes. Pituitary ablation has been used to treat severe retinopathy with some success (Luft, Olwercroner and Sjogren, 1955; Joplin et al., 1965; Cullen et al., 1971; Kohner et al., 1976) , and Lundbaek et al. (1970 and Lundbaek et al. ( , 1971 have suggested a causal relationship between GH and the development of retinopathy in diabetics. This is also suggested by the report that retinopathy is worsened when GH is administered to pituitary-ablated patients (Ray et al., 1968) . Secretion of GH is abnormal in some diabetics, plasma levels being elevated with more frequent and higher peaks compared to normal subjects (Corral et al., 1974 as exercise (Hansen, 1970; 1971) , glucose loading (Knopf et al., 1973) , arginine (Passa et al., 1977) , glucagon (Waldhausl et al., 1976) (Lundbaek, 1976) then such diabetics would be even more likely to be exposed to high plasma GH levels for long periods of time with adverse consequences.
